Ari Bousbib, Chairman, Chief Executive Officer and President of Quintiles IMS Holdings, Inc. (NYSE:Q) said, ". In the quarter, I think we spent $180 million in acquisitions. We continuously look for and have a rich pipeline of small tuck-in capability acquisitions. These are, for the most part, and I want to say exclusively this year, technology acquisitions, both in the commercial space and the clinical space. This quarter, there were a few handful of small acquisitions, all of which closed at the end of the quarter and had 0 impact in the quarter. As we've told you before, we may pay a healthy premium because again, we're buying technology capabilities. It's a decision to continue to develop our assets through acquisitions instead of internal product development spend. Initially, this acquisitions have very little revenue contribution and the acquisition spend can be lumpy quarter-to-quarter. But that's what we signaled before. It's not rich. And we expect, to answer your question in terms of contribution to revenue, that acquisitions will contribute year in, year out, 1 point, 1.5 points to our growth, and this year won't be different."
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).